© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
selective oral Wee1 kinase inh. (300 mg QD)
Ph. II candidate for uterine serous carcinoma
from literature starting point
Journal of Medicinal Chemistry
Zentalis Pharmaceuticals, San Diego, CA, USA
The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.